|
WO2016094679A1
(en)
|
2014-12-10 |
2016-06-16 |
Regents Of The University Of Minnesota |
Genetically modified cells, tissues, and organs for treating disease
|
|
EP3294342A4
(en)
|
2015-05-08 |
2018-11-07 |
President and Fellows of Harvard College |
Universal donor stem cells and related methods
|
|
WO2017093969A1
(en)
|
2015-12-04 |
2017-06-08 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
KR20240095477A
(ko)
*
|
2017-01-13 |
2024-06-25 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
면역조작된 만능 세포
|
|
EP3601528A4
(en)
*
|
2017-03-20 |
2021-05-05 |
Washington University |
Cells and methods of uses and making the same
|
|
KR20190130608A
(ko)
|
2017-03-22 |
2019-11-22 |
노파르티스 아게 |
면역종양학을 위한 조성물 및 방법
|
|
CN110869494B
(zh)
|
2017-06-12 |
2025-02-18 |
西奈卫生系统公司 |
无需全身性免疫遏制的同种异体移植物耐受
|
|
EP3652312A1
(en)
|
2017-07-14 |
2020-05-20 |
Editas Medicine, Inc. |
Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
|
|
AU2019305585A1
(en)
*
|
2018-07-17 |
2021-01-28 |
The Regents Of The University Of California |
Cells differentiated from immunoengineered pluripotent cells
|
|
EP3824075A4
(en)
*
|
2018-07-17 |
2022-04-20 |
The Regents of The University of California |
CHIMERA ANTIGEN RECEPTOR T-CELLS DERIVED FROM IMMUNOMANIPULATED PLURIPOTENTS STEM CELLS
|
|
US12378572B2
(en)
|
2018-09-07 |
2025-08-05 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
CN113195724A
(zh)
*
|
2018-09-26 |
2021-07-30 |
新加坡国立大学 |
低免疫原性的工程化人类间充质基质细胞，制备方法和试剂盒
|
|
UY38427A
(es)
*
|
2018-10-26 |
2020-05-29 |
Novartis Ag |
Métodos y composiciones para terapia con células oculares
|
|
CA3123102A1
(en)
|
2018-12-13 |
2020-06-18 |
Sinai Health System |
Immunomodulatory cells and uses thereof
|
|
CN111424016A
(zh)
*
|
2019-01-09 |
2020-07-17 |
复旦大学 |
降低细胞免疫原性的诱导型多能干细胞系及建立方法
|
|
SG11202108891QA
(en)
*
|
2019-02-15 |
2021-09-29 |
Harvard College |
Universal donor stem cells and related methods
|
|
US20220213434A1
(en)
|
2019-05-10 |
2022-07-07 |
The Regents Of The University Of California |
Modified pluripotent cells
|
|
US11162079B2
(en)
|
2019-05-10 |
2021-11-02 |
The Regents Of The University Of California |
Blood type O Rh-hypo-immunogenic pluripotent cells
|
|
US12391923B2
(en)
|
2019-06-26 |
2025-08-19 |
The Regents Of The University Of California |
SIRPα-silenced natural killer (NK) cells
|
|
TW202115245A
(zh)
*
|
2019-06-27 |
2021-04-16 |
丹麥商諾佛 儂迪克股份有限公司 |
安全免疫隱形細胞
|
|
US20220333082A1
(en)
|
2019-07-10 |
2022-10-20 |
Helmuth Heinrich Kunz |
Methods for deriving autologous and hypoimmunogenic hair follicle containing sheets in vitro
|
|
EP4007596A1
(en)
*
|
2019-08-01 |
2022-06-08 |
Sana Biotechnology, Inc. |
Dux4 expressing cells and uses thereof
|
|
JP7728747B2
(ja)
|
2019-08-23 |
2025-08-25 |
サナ バイオテクノロジー，インコーポレイテッド |
Ｃｄ２４発現細胞およびそれらの用途
|
|
US11116798B2
(en)
|
2019-09-05 |
2021-09-14 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
US11104918B2
(en)
|
2019-09-05 |
2021-08-31 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
US12551560B2
(en)
|
2019-09-09 |
2026-02-17 |
Scribe Therapeutics Inc. |
Compositions and methods for use in immunotherapy
|
|
WO2021055985A1
(en)
*
|
2019-09-22 |
2021-03-25 |
Cellerant Therapeutics, Inc. |
Ipsc-derived, hypoimmunogenic, myeloid progenitor cells
|
|
EP4045648A4
(en)
*
|
2019-10-15 |
2023-11-22 |
The Regents of The University of California |
Transplanted cell protection via fc sequestration
|
|
JP7853210B2
(ja)
*
|
2020-01-13 |
2026-04-28 |
サナ バイオテクノロジー，インコーポレイテッド |
血液型抗原の修飾
|
|
EP4585223A3
(en)
|
2020-01-15 |
2025-07-30 |
The Regents of the University of California |
Transplanted cell protection via inhibition of polymorphonuclear cells
|
|
EP4090747A1
(en)
|
2020-01-17 |
2022-11-23 |
Sana Biotechnology, Inc. |
Safety switches for regulation of gene expression
|
|
EP4125961A1
(en)
*
|
2020-03-25 |
2023-02-08 |
Sana Biotechnology, Inc. |
Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
|
|
WO2021207121A1
(en)
*
|
2020-04-06 |
2021-10-14 |
Rxcell Inc. |
Hypoimmunogenic cells and methods and compositions for their production
|
|
EP4138893A4
(en)
*
|
2020-04-21 |
2024-06-12 |
Intima Bioscience, Inc. |
Cellular vaccine platform and methods of use
|
|
JP2023525579A
(ja)
*
|
2020-05-15 |
2023-06-16 |
アールエックスセル インコーポレーテッド |
低免疫原性の細胞および免疫応答におけるそれらの使用
|
|
AU2021325941A1
(en)
|
2020-08-13 |
2023-03-09 |
Sana Biotechnology, Inc. |
Methods of treating sensitized patients with hypoimmunogenic cells, and associated methods and compositions
|
|
CN112342196A
(zh)
*
|
2020-08-18 |
2021-02-09 |
未来智人再生医学研究院(广州)有限公司 |
一种免疫兼容可逆的通用型多能干细胞及其应用
|
|
IL301972A
(en)
*
|
2020-10-09 |
2023-06-01 |
Sana Biotechnology Inc |
Methods for activating safe killing mechanisms using the CD47–SIRPα blocking factor
|
|
CA3196346A1
(en)
*
|
2020-10-20 |
2022-04-28 |
Herman Waldmann |
Methods and compositions for cellular therapy
|
|
CN114525255A
(zh)
*
|
2020-10-30 |
2022-05-24 |
未来智人再生医学研究院(广州)有限公司 |
一种表达il-11的多能干细胞衍生物及其应用
|
|
CN114457021A
(zh)
*
|
2020-10-30 |
2022-05-10 |
未来智人再生医学研究院(广州)有限公司 |
一种表达cd47抗体的多能干细胞及其衍生物与应用
|
|
US11459372B2
(en)
|
2020-11-30 |
2022-10-04 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
US11661459B2
(en)
|
2020-12-03 |
2023-05-30 |
Century Therapeutics, Inc. |
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
|
|
IL303269A
(en)
|
2020-12-03 |
2023-07-01 |
Century Therapeutics Inc |
Genetically engineered cells and uses thereof
|
|
CN114107211B
(zh)
*
|
2020-12-04 |
2025-09-30 |
未来智人再生医学研究院(广州)有限公司 |
一种多能干细胞及其衍生物
|
|
CN116829698A
(zh)
*
|
2020-12-07 |
2023-09-29 |
加利福尼亚大学董事会 |
通过SIRP-α衔接体的先天免疫细胞沉默
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
US11965022B2
(en)
|
2020-12-31 |
2024-04-23 |
Sana Biotechnology, Inc. |
Methods and compositions for modulating CAR-T activity
|
|
US11566230B2
(en)
|
2020-12-31 |
2023-01-31 |
Crispr Therapeutics Ag |
Universal donor cells
|
|
CA3212370A1
(en)
|
2021-03-03 |
2022-09-09 |
Sana Biotechnology, Inc. |
Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions
|
|
WO2022191216A1
(ja)
*
|
2021-03-09 |
2022-09-15 |
国立研究開発法人理化学研究所 |
低免疫原性網膜色素上皮細胞の製造方法
|
|
AU2022249039A1
(en)
*
|
2021-03-30 |
2023-09-28 |
The Regents Of The University Of California |
Transplanted cell protection via modified fc receptors
|
|
EP4323501A1
(en)
*
|
2021-04-16 |
2024-02-21 |
Beam Therapeutics Inc. |
Genetic modification of hepatocytes
|
|
CA3219830A1
(en)
*
|
2021-05-24 |
2022-12-01 |
Lei Zhang |
Ciita targeting zinc finger nucleases
|
|
US20240226164A1
(en)
|
2021-05-27 |
2024-07-11 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cells comprising engineered hla-e or hla-g
|
|
CA3225283A1
(en)
|
2021-07-14 |
2023-01-19 |
Sonja SCHREPFER |
Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
|
|
KR102847814B1
(ko)
*
|
2021-07-28 |
2025-08-21 |
의료법인 성광의료재단 |
B2m 유전자의 발현이 저해된 유전적으로 조작된 줄기세포 및 이의 이용방법
|
|
US20260053851A1
(en)
|
2021-08-11 |
2026-02-26 |
Sana Biotechnology, Inc. |
Inducible systems for altering gene expression in hypoimmunogenic cells
|
|
AU2022326565A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy
|
|
AU2022325231A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
|
|
CA3227108A1
(en)
|
2021-08-11 |
2023-02-16 |
Xiaomeng HU |
Genetically modified primary cells for allogeneic cell therapy
|
|
AU2022325955A1
(en)
|
2021-08-11 |
2024-02-08 |
Sana Biotechnology, Inc. |
Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
|
|
CN117904109A
(zh)
*
|
2021-08-27 |
2024-04-19 |
浙江大学 |
一种超级增强子核心序列调控b2m基因表达的效果及应用
|
|
US20250313861A1
(en)
|
2021-10-22 |
2025-10-09 |
Sana Biotechnology, Inc. |
Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
|
|
WO2023122337A1
(en)
|
2021-12-23 |
2023-06-29 |
Sana Biotechnology, Inc. |
Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
|
|
CA3246902A1
(en)
*
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
DIFFERENTIATED HYPOIMMUNOUS BETA CELLS FROM PURIPOTENTIC STEM CELLS AND RELATED USES AND METHODS
|
|
EP4479084A1
(en)
|
2022-02-14 |
2024-12-25 |
Sana Biotechnology, Inc. |
Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
|
|
WO2023158836A1
(en)
|
2022-02-17 |
2023-08-24 |
Sana Biotechnology, Inc. |
Engineered cd47 proteins and uses thereof
|
|
WO2023173123A1
(en)
|
2022-03-11 |
2023-09-14 |
Sana Biotechnology, Inc. |
Genetically modified cells and compositions and uses thereof
|
|
WO2023183313A1
(en)
|
2022-03-22 |
2023-09-28 |
Sana Biotechnology, Inc. |
Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
|
|
CN114958768B
(zh)
*
|
2022-06-02 |
2023-03-24 |
健颐生物科技发展(山东)有限公司 |
Fgf10旁分泌通用型人成纤维细胞制剂的制备方法
|
|
CN117343962A
(zh)
*
|
2022-06-29 |
2024-01-05 |
中国科学院上海营养与健康研究所 |
免疫兼容型人多能干细胞、其制备方法及应用
|
|
EP4547825A1
(en)
|
2022-07-01 |
2025-05-07 |
Novo Nordisk A/S |
Enhancing neuronal differentiation of ventral midbrain neural progenitor cells
|
|
WO2024012420A1
(zh)
*
|
2022-07-11 |
2024-01-18 |
士泽生物医药（苏州）有限公司 |
一种表达faslg的通用型细胞及其制备方法
|
|
CN117431217A
(zh)
*
|
2022-07-12 |
2024-01-23 |
上海驯鹿生物技术有限公司 |
表达靶向cd5的嵌合抗原受体(car)的细胞及其应用
|
|
GB202211117D0
(en)
*
|
2022-07-29 |
2022-09-14 |
Replay Holdings Llc |
Compositions and methods for non-immunogenecity
|
|
GB202212144D0
(en)
*
|
2022-08-19 |
2022-10-05 |
Resolution Therapeutics Ltd |
Cells for therapy
|
|
WO2024097313A1
(en)
|
2022-11-02 |
2024-05-10 |
Sana Biotechnology, Inc. |
Methods for producing t cell therapy products
|
|
EP4619015A1
(en)
*
|
2022-11-15 |
2025-09-24 |
The Board of Trustees of the Leland Stanford Junior University |
Hypoallogenic-immunogenic pluripotent stem cells as anti-cancer vaccine
|
|
CN118147077B
(zh)
*
|
2022-12-07 |
2025-09-26 |
士泽生物医药（苏州）有限公司 |
一种表达gsn的通用型细胞及其制备方法
|
|
CN118207165B
(zh)
*
|
2022-12-07 |
2026-03-20 |
士泽生物医药（苏州）有限公司 |
一种表达stc1的通用型细胞及其制备方法
|
|
GB202218755D0
(en)
*
|
2022-12-13 |
2023-01-25 |
Replay Holdings Llc |
Compositions and methods for non-immunogenicity
|
|
CN118207166A
(zh)
*
|
2022-12-16 |
2024-06-18 |
士泽生物医药（苏州）有限公司 |
一种通用型细胞及其制备方法
|
|
WO2024151541A1
(en)
|
2023-01-09 |
2024-07-18 |
Sana Biotechnology, Inc. |
Type-1 diabetes autoimmune mouse
|
|
WO2024169917A1
(zh)
*
|
2023-02-16 |
2024-08-22 |
士泽生物医药（苏州）有限公司 |
通用型细胞及其制备方法
|
|
CN121843705A
(zh)
|
2023-05-03 |
2026-04-10 |
萨那生物科技公司 |
工程化胰岛细胞的给药和施用方法
|
|
WO2024243236A2
(en)
|
2023-05-22 |
2024-11-28 |
Sana Biotechnology, Inc. |
Methods of delivery of islet cells and related methods
|
|
EP4735585A1
(en)
|
2023-06-30 |
2026-05-06 |
Novo Nordisk A/S |
Enhancing neuronal differentiation of neural progenitor cells
|
|
KR102740042B1
(ko)
*
|
2023-07-12 |
2024-12-06 |
㈜바이오솔빅스 |
인간 전분화능 줄기세포로 유래된 심장 오가노이드 제조방법, 효능 및 독성 평가 기술
|
|
WO2025043172A1
(en)
|
2023-08-23 |
2025-02-27 |
Sana Biotechnology, Inc. |
Modified cd47 proteins and their uses
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
CN119351338B
(zh)
*
|
2023-09-15 |
2026-01-23 |
士泽生物医药（苏州）有限公司 |
一种表达cd300ld的低免疫原性细胞及其制备方法
|
|
WO2025096757A1
(en)
|
2023-11-01 |
2025-05-08 |
Sana Biotechnology, Inc. |
Hypoimmunogenic cd22-targeted car t cells for the treatment of relapsed and/or refractory b cell lymphomas
|
|
AU2025208175A1
(en)
|
2024-01-12 |
2026-06-25 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025230947A1
(en)
|
2024-04-30 |
2025-11-06 |
Satellite Biosciences, Inc. |
Engineered hepatocytes for secreting polypeptides
|
|
WO2025230941A1
(en)
|
2024-04-30 |
2025-11-06 |
Satellite Biosciences, Inc. |
Hypoimmunogenic cell mixtures and methods of use thereof
|
|
CN121006322A
(zh)
*
|
2024-05-22 |
2025-11-25 |
上海苹谱医疗科技有限公司 |
一种通用型工程化细胞及其制备方法与应用
|
|
WO2025259640A1
(en)
*
|
2024-06-14 |
2025-12-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Systems and methods for bioengineering hypoimmunogenic organs, tissues and cells
|
|
WO2026072871A1
(en)
*
|
2024-09-26 |
2026-04-02 |
Sana Biotechnology, Inc. |
Alternative sources of tissue
|